Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Adipose-derived mesenchymal stem cell exosomes protect keratinocytes from high-glucose injury by modulating KEAP1/NRF2/HO-1 axis.

Yuan Y., Song S., Xiao Y., Feng R., Li M., Zhang H.

Animal Study on Diabetic Foot, Chronic Wound, published in Cell Signal (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cell Signal (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41101367
DOI
10.1016/j.cellsig.2025.112172

Abstract (original English)

Hyperglycemia exacerbates diabetic chronic wounds by inducing oxidative damage and epithelial-mesenchymal transition (EMT), impairing re-epithelialization. This study investigated the protective role of adipose-derived mesenchymal stem cell exosomes (ADSC-Exos) against high glucose (HG)-induced keratinocyte injury and diabetic wound healing impairment. ADSC-Exos were isolated via density gradient ultracentrifugation, characterized using NTA, TEM, and immunoblotting, and applied to HG-treated HaCaT cells and diabetic mouse wounds. In vitro, ADSC-Exos significantly mitigated HG-induced oxidative stress by reducing reactive oxygen species (ROS), DNA damage (8-OHdG), and lipid peroxidation (MDA), while enhancing antioxidant enzymes (SOD, CAT). Mechanistically, ADSC-Exos suppressed KEAP1, activated the NRF2/HO-1 pathway, and attenuated pathological EMT-like changes by restoring E-cadherin and suppressing N-cadherin, α-SMA, and Vimentin. In diabetic mice, ADSC-Exos accelerated wound closure, improved collagen deposition, and reduced inflammatory cytokines (IL-1β, IL-6, TNF-α). These findings demonstrate that ADSC-Exos promote diabetic wound healing by alleviating oxidative stress and pathological EMT-like changes via KEAP1/NRF2/HO-1 signaling, supporting their potential as a therapeutic strategy for diabetic chronic wounds.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ExosomesNF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1AnimalsMesenchymal Stem CellsHumansKeratinocytesGlucoseMiceOxidative Stress

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research